A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib-Reference-Cited by-同舟云学术

A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib

Published:2022-02-14 Issue:4 Volume:39 Page:1678-1696
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Proudman David,Nellesen Dave,Gupta Deepshekhar,Adib Deyaa,Yang Jay,Mamlouk Khalid

Funder

Epizyme, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02054-z.pdf

Reference32 articles.

1. Surveillance Epidemiology and End Results Program. SEER Cancer Stat Facts: NHL - Follicular Lymphoma. 2020. https://seer.cancer.gov/statfacts/html/follicular.html. Accessed Mar 27 2020.

2. Alperovich A, Batlevi C, Smith K, et al. Benchmark of progression-free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era [abstract]. Presented at: 58th American Society of Hematology Annual Meeting and Exposition; December 3–6, 2016; San Diego, CA.

3. Zydelig [package insert]. Foster City, CA: Gilead Sciences Inc., 2018.

4. Copiktra [package insert]. Needham, MA: Verastem, Inc., 2019.

5. Aliqopa [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, 2020.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion;2024-05-17

2. Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective;BMC Public Health;2024-02-12

3. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-02

4. Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective;2023-10-02

5. Recent advances in treatment of nodal and gastrointestinal follicular lymphoma;World Journal of Gastroenterology;2023-06-21